Enhancing Function Using the RF Microstimulator Gait System Following Stroke 2008
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Stroke
- Sponsor
- US Department of Veterans Affairs
- Enrollment
- 1
- Locations
- 1
- Primary Endpoint
- Walking Endurance (6MWT)
- Status
- Terminated
- Last Updated
- 11 years ago
Overview
Brief Summary
The purpose of the study is to investigate new Technology for recovery of ankle walking function after stroke.
Detailed Description
Background and Purpose: Conventional rehabilitation does not restore normal, upper limb function or normal gait to many stroke survivors. Functional neuromuscular stimulation (FNS) has shown promise for functional enhancement of both upper and lower limb motor control following stroke. Gains included muscle activation latencies, strength, coordination, upper limb functional tasks, gait kinematics, walking endurance, and quality of life. The purpose of the proposed work is to test the radio frequency-controlled (RF) Microstimulator (RFM) Gait System regarding system performance and subject response to treatment. Methods: This is a feasibility study in which up to four subjects will receive the (RFM) Gait System. Up to ten RFMs will be placed for a given subject. An RFM ankle muscle system will be used to train ankle gait components. A separate RFM system will be used to train knee gait components. Subjects will be treated for 6 months, four sessions/wk. Primary outcome measures for the RFM Gait System will be: kinematic swing phase gait components and walking endurance. Secondary outcome measures will include: strength, coordination, spasticity, function, and quality of life. Data collections will occur at months 1, 3 and 6, and for follow-up times up to a year after the end of treatment. The results of the RFM ankle system have the potential to provide a new technology for ankle muscle gait components.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Sufficient endurance to participate in rehabilitation sessions.
- •Medically Stable
- •Age \>21 years.
- •Inability to perform normal ankle coordinated gait components.
- •Participants should be able to walk and keep balance without physical assistance from another person
Exclusion Criteria
- •Acute or progressive cardiac, renal, respiratory, neurological disorders or malignancy.
- •Lower motor neuron damage or radiculopathy
- •Allergy or contraindication to anesthesia, Versed, (or comparable substitute.
- •Active implantable device (e.g. pacemaker, implantable cardiac defibrillator, neurostimulator, or drug infusion device.
- •Pregnancy
Outcomes
Primary Outcomes
Walking Endurance (6MWT)
Time Frame: Day 1 and at 3 months, following treatment
The Six Minute Walk Test (6MWT) is a measure of the distance measured in feet ambulated by the participant during six minutes. A further distance walked in 6 minutes indicates improvement on the measure.
Kinematic Gait Measures
Time Frame: Day 1 and at 3 months, following treatment
assessment of the lower limb kinematics during ambulation at chosen speed.
Secondary Outcomes
- Fugl-Meyer Lower Extremity Score(Day 1 and at 3 months, following treatment)
- Ashworth Scale(Day 1 and at 3 months, following treatment)
- Stroke Impact Scale (SIS)(Day 1 and at 3 months, following treatment)
- Manual Muscle Testing (MMT)(Day 1 and at 3 months, following treatment)